Haemonetics (Haemonetics) Total Inventories

: $304 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Haemonetics's total inventories for the quarter that ended in Dec. 2023 was $304 Mil. Haemonetics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $295 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Haemonetics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-14.82.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Haemonetics's Days Inventory for the three months ended in Dec. 2023 was 169.92.

Inventory Turnover measures how fast the company turns over its inventory within a year. Haemonetics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.54.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Haemonetics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.

Haemonetics Total Inventories Historical Data

The historical data trend for Haemonetics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Inventories

194.34

270.28

322.61

293.03

259.38

Haemonetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories																255.76	259.38	289.21	285.83	304.02

Haemonetics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Haemonetics (NYSE:HAE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Haemonetics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(193.978	+	0.75 * 211.611	+	0.5 * 304.024	-	1257.109
-	0	-	0)	/	50.785
=	-14.82

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Haemonetics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	294.927	/	158.383	*	365 / 4
	=	169.92

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Haemonetics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	158.383	/	294.927
	=	0.54

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Haemonetics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	294.927	/	336.25
	=	0.88

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Haemonetics Total Inventories Related Terms

Thank you for viewing the detailed overview of Haemonetics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (Haemonetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

HAZ:Germany

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Executives

Stewart W Strong	officer: President, Global Hospital	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni	officer: EVP, Chief Technology Officer	HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant	director	2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens	officer: EVP, Global Manufacturing	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil	officer: EVP and General Counsel	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell	officer: VP, Chief Accounting Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin	officer: President, Global Plasma & BC	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller	officer: SVP, Human Resources	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll	director	PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein	officer: VP, Corporate Controller	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon,	director, officer: President & CEO	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca	officer: EVP, Chief Financial Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr.	officer: EVP, Chief Financial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson	director	16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277